74 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core.
Vitae Pharmaceuticals
Discovery of a 2-hydroxyacetophenone derivative as an outstanding linker to enhance potency andß-selectivity of liver X receptor agonist.
Kowa
Discovery of a Novel, Orally Efficacious Liver X Receptor (LXR)ß Agonist.
Vitae Pharmaceuticals
Identification and in Vivo Evaluation of Liver X Receptorß-Selective Agonists for the Potential Treatment of Alzheimer's Disease.
Wuxi Apptec
Altered activity profile of a tertiary silanol analog of multi-targeting nuclear receptor modulator T0901317.
The University Of Tokyo
Styrylphenylphthalimides as Novel Transrepression-Selective Liver X Receptor (LXR) Modulators.
The University Of Tokyo
Discovery and structure-guided optimization of tert-butyl 6-(phenoxymethyl)-3-(trifluoromethyl)benzoates as liver X receptor agonists.
Daiichi Sankyo Rd Novare
Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists.
Genentech
Design, synthesis and pharmacology of 1,1-bistrifluoromethylcarbinol derivatives as liver X receptorß-selective agonists.
Kowa
Minor Structural Change to Tertiary Sulfonamide RORc Ligands Led to Opposite Mechanisms of Action.
Genentech
Design and discovery of 2-oxochromene derivatives as liver X receptorß-selective agonists.
Kowa
Reduction in lipophilicity improved the solubility, plasma-protein binding, and permeability of tertiary sulfonamide RORc inverse agonists.
Genentech
Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-¿ (ROR¿ or RORc).
Genentech
Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRß.
Bristol-Myers Squibb
Structure-activity relationship-guided development of retinoic acid receptor-related orphan receptor gamma (ROR¿)-selective inverse agonists with a phenanthridin-6(5H)-one skeleton from a liver X receptor ligand.
The University Of Tokyo
Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc.
Genentech
Cyanidin, a natural flavonoid, is an agonistic ligand for liver X receptor alpha and beta and reduces cellular lipid accumulation in macrophages and hepatocytes.
Korea University
Induction of ABCA1 and ABCG1 expression by the liver X receptor modulator cineole in macrophages.
Korea University
Identification of Potent and Selective Diphenylpropanamide ROR? Inhibitors.
New York University School Of Medicine
Discovery of tertiary sulfonamides as potent liver X receptor antagonists.
Glaxosmithkline
Ethyl 2,4,6-trihydroxybenzoate is an agonistic ligand for liver X receptor that induces cholesterol efflux from macrophages without affecting lipid accumulation in HepG2 cells.
Korea University
Design, synthesis, and biological evaluation of novel transrepression-selective liver X receptor (LXR) ligands with 5,11-dihydro-5-methyl-11-methylene-6H-dibenz[b,e]azepin-6-one skeleton.
The University Of Tokyo
Identification of diaryl ether-based ligands for estrogen-related receptora as potential antidiabetic agents.
Johnson & Johnson Pharmaceutical Research And Development
3-(3-Aryloxyaryl)imidazo[1,2-a]pyridine sulfones as liver X receptor agonists.
Wyeth Pharmaceuticals
Discovery and development of dimeric podocarpic acid leads as potent agonists of liver X receptor with HDL cholesterol raising activity in mice and hamsters.
Merck Research Laboratories
Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.
Phenex Pharmaceuticals
Synthesis of 4-(3-biaryl)quinoline sulfones as potent liver X receptor agonists.
Wyeth Pharmaceuticals
Identification of phenylsulfone-substituted quinoxaline (WYE-672) as a tissue selective liver X-receptor (LXR) agonist.
Wyeth Pharmaceuticals
1-(3-Aryloxyaryl)benzimidazole sulfones are liver X receptor agonists.
Wyeth Pharmaceuticals
Quinoline-3-carboxamide containing sulfones as liver X receptor (LXR) agonists with binding selectivity for LXRbeta and low blood-brain penetration.
Wyeth Pharmaceuticals
4-(3-Aryloxyaryl)quinoline sulfones are potent liver X receptor agonists.
Wyeth Pharmaceuticals
The discovery of tertiary-amine LXR agonists with potent cholesterol efflux activity in macrophages.
Glaxosmithkline
Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXRalpha-selective antagonists.
The University Of Tokyo
Discovery and SAR of cinnolines/quinolines as liver X receptor (LXR) agonists with binding selectivity for LXRbeta.
Wyeth Research
Liver X receptor agonists with selectivity for LXRbeta; N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropionamides.
Astrazeneca R&D SöDertäLje
Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity.
Glaxosmithkline
Anthrabenzoxocinones from Streptomyces sp. as liver X receptor ligands and antibacterial agents.
Merck Research Laboratories
Diterpenoid, steroid, and triterpenoid agonists of liver X receptors from diversified terrestrial plants and marine sources.
Merck Research Laboratories
Guttiferone I, a new prenylated benzophenone from Garcinia humilis as a liver X receptor ligand.
Merck Research Laboratories
Carboxylic acid based quinolines as liver X receptor modulators that have LXRbeta receptor binding selectivity.
Wyeth Pharmaceuticals
Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors.
University Of Tokyo
Synthesis and evaluation of anilinohexafluoroisopropanols as activators/modulators of LXRalpha and beta.
F. Hoffmann-La Roche
Design, synthesis, and structure-activity relationship of podocarpic acid amides as liver X receptor agonists for potential treatment of atherosclerosis.
Merck Research Laboratories
Discovery of a potent orally bioavailable retinoic acid receptor-related orphan receptor-gamma-t (ROR?t) inhibitor, S18-000003.
Shionogi
Recent Advances in the Medicinal Chemistry of Liver X Receptors.
Saint Louis University School Of Medicine
Structural development of tetrachlorophthalimides as liver X receptor ? (LXR?)-selective agonists with improved aqueous solubility.
The University Of Tokyo
Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (ROR?/RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivity.
Bristol-Myers Squibb
Novel Nonsteroidal Progesterone Receptor (PR) Antagonists with a Phenanthridinone Skeleton.
The University Of Tokyo
Indazole-based ligands for estrogen-related receptor ? as potential anti-diabetic agents.
Janssen Research And Development
DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators.
Goethe-University Frankfurt
Side-Chain Modified Ergosterol and Stigmasterol Derivatives as Liver X Receptor Agonists.
Universit£
Bisubstrate inhibitors of the enzyme catechol O-methyltransferase (COMT): efficient inhibition despite the lack of a nitro group.
Laboratorium FÜR Organische Chemie
Species orthologs of the alpha-2A adrenergic receptor: the pharmacological properties of the bovine and rat receptors differ from the human and porcine receptors.
University Of Nebraska
Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.
Yamanouchi Pharmaceutical